Bulgaria’s Commission for Protection of Competition (CPC) announced on Thursday, March 18, that it approved the acquisition of Waste Solutions, the parent of waste management company Waste Solutions Bulgaria, by private investor Kiril Tarev.
The notified transaction is not expected to have an impact on any of the local markets, as the parties to the deal operate in different sectors, the antitrust body stated in its decision.
Currently, Waste Solutions is 90%-owned by private individual Anton Stratiev. The remaining 10% interest is owned by local company Antonov Eco Consult.
According to the competition authority, Kiril Tarev signed a preliminary sales agreement with Anton Stratiev on December 18, for the acquisition of 90% interest in Waste Solutions which will make it an indirect shareholder in Waste Solutions Bulgaria. The parties agreed to close the deal within a period of 90 days since the signing of the preliminary sales agreement but not before the issuing of a permit by the relevant regulator. Financial details of the agreement were not disclosed.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Johns Hopkins and Caltech Settle for $35.3M in College Price-Fixing Lawsuit
Jan 22, 2025 by
CPI
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan